MiRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma

Pancreas

Volumn 45, Issue 1, 2016, Pages 84-92

  Alemar, Bárbara ^a,b   Izetti, Patrícia ^a,b   Gregório, Cleandra ^a,b   Macedo, Gabriel S ^a,b   Castro, Mauro Antonio Alves ^b,c   Osvaldt, Alessandro Bersch ^b,d   Matte, Ursula ^a,b   Ashton Prolla, Patricia ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d Programa de Pós Graduação em Medicina Ciências Cirúrgicas   (Brazil)

Author keywords

microRNAs; miR 21; miR 34a; pancreatic ductal adenocarcinoma; salivary biomarkers; serum biomarkers

Indexed keywords

MICRORNA 155; MICRORNA 196A; MICRORNA 200B; MICRORNA 21; MICRORNA 34A; MICRORNA 376A; UNCLASSIFIED DRUG; MICRORNA; MIRN21 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SALIVATION; TUMOR SUPPRESSOR GENE; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; EVALUATION STUDY; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PILOT STUDY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVA;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SALIVA;

EID: 84952705314     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000383     Document Type: Article

References (58)

1. Siegel R, Ma J, Zou Z, Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Rhim AD, Mirek ET, Aiello NM, EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148: 349-361.
3. Li D, Xie K, Wolff R, Pancreatic cancer. Lancet. 2004; 363: 1049-1057.
4. Olive KP, Jacobetz MA, Davidson CJ, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324: 1457-1461.
5. Vincent A, Herman J, Schulick R, Pancreatic cancer. Lancet. 2011; 378: 607-620.
6. Hidalgo M,. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-1617.
7. Mayo SC, Austin DF, Sheppard BC, Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg. 2009; 208: 87-95.
8. Samuel N, Hudson TJ,. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 9: 77-87.
9. Jones S, Zhang X, Parsons DW, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
10. Harsha HC, Kandasamy K, Ranganathan P, A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009; 6: e1000046.
11. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
12. Lu J, Getz G, Miska EA, MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838.
13. Bloomston M, Frankel WL, Petrocca F, MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297: 1901-1908.
14. Szafranska AE, Davison TS, John J, MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26: 4442-4452.
15. Lee EJ, Gusev Y, Jiang J, Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120: 1046-1054.
16. Zhang Y, Li M, Wang H, Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2009; 33: 698-709.
17. Kent OA, Mullendore M, Wentzel EA, A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009; 8: 2013-2024.
18. Lawrie CH, Gal S, Dunlop HM, Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141: 672-675.
19. Chen X, Ba Y, Ma L, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006.
20. Mitchell PS, Parkin RK, Kroh EM, Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-10518.
21. Kosaka N, Iguchi H, Ochiya T,. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101: 2087-2092.
22. Arroyo JD, Chevillet JR, Kroh EM, Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108: 5003-5008.
23. Gallo A, Tandon M, Alevizos I, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7: e30679.
24. Chevillet JR, Lee I, Briggs HA, Issues and prospects of microRNA-based biomarkers in blood and other body fluids. Molecules. 2014; 19: 6080-6105.
25. Morimura R, Komatsu S, Ichikawa D, Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011; 105: 1733-1740.
26. Chang TC, Wentzel EA, Kent OA, Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26: 745-752.
27. Franzmann EJ, Reategui EP, Carraway KL, Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 735-739.
28. Brooks MN, Wang J, Li Y, Salivary protein factors are elevated in breast cancer patients. Mol Med Rep. 2008; 1: 375-378.
29. Zhang L, Farrell JJ, Zhou H, Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010; 138: 949-957. e1-7.
30. Hanson EK, Lubenow H, Ballantyne J,. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem. 2009; 387: 303-314.
31. Xie Z, Chen G, Zhang X, Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One. 2013; 8: e57502.
32. Matse JH, Yoshizawa J, Wang X, Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors. Clin Cancer Res. 2013; 19: 3032-3038.
33. Park NJ, Zhou H, Elashoff D, Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15: 5473-5477.
34. Bosman F, Carneiro F, Hruban R, WHO Classification of Tumours of the Digestive System. 7th ed. Geneva, Switzerland: WHO Press; 2010.
35. Li Y, St John MA, Zhou X, Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004; 10: 8442-8450.
36. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408.
37. Schmittgen TD, Livak KJ,. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101-1108.
38. Li Y, Kowdley KV,. Method for microRNA isolation from clinical serum samples. Anal Biochem. 2012; 431: 69-75.
39. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20.
40. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57.
41. Resnick KE, Alder H, Hagan JP, The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009; 112: 55-59.
42. Tanaka M, Oikawa K, Takanashi M, Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009; 4: e5532.
43. Heneghan HM, Miller N, Lowery AJ, Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251: 499-505.
44. Wang J, Chen J, Chang P, MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009; 2: 807-813.
45. Kong X, Du Y, Wang G, Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011; 56: 602-609.
46. Liu R, Chen X, Du Y, Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012; 58: 610-618.
47. Schultz NA, Dehlendorff C, Jensen BV, MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014; 311: 392-404.
48. du Rieu MC, Torrisani J, Selves J, MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem. 2010; 56: 603-612.
49. Giovannetti E, Funel N, Peters GJ, MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70: 4528-4538.
50. Moriyama T, Ohuchida K, Mizumoto K, MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009; 8: 1067-1074.
51. Calhoun ES, Hucl T, Gallmeier E, Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 2006; 66: 7920-7928.
52. Ji Q, Hao X, Zhang M, MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009; 4: e6816.
53. Dutta KK, Zhong Y, Liu YT, Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 2007; 98: 1845-1852.
54. Wang M, Zhang P, Li Y, The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med Oncol. 2012; 29: 3113-3118.
55. Eichelser C, Flesch-Janys D, Chang-Claude J, Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013; 59: 1489-1496.
56. Wulfken LM, Moritz R, Ohlmann C, MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011; 6: e25787.
57. Pigati L, Yaddanapudi SC, Iyengar R, Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010; 5: e13515.
58. Ma X, Yoshimoto K, Guan Y, Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol. 2012; 14: 1153-1162.